公开(公告)号：US20140155413A1

公开(公告)日：2014-06-05

申请号：US14131861

申请日：2012-07-06

申请人： Barbara Hanney ,  Peter Manley ,  Michael T. Rudd ,  John M. Sanders ,  Shawn J. Stachel ,  Darrell Henze

发明人： Barbara Hanney ,  Peter Manley ,  Michael T. Rudd ,  John M. Sanders ,  Shawn J. Stachel ,  Darrell Henze

IPC分类号： C07D471/04 ,  C07D417/04 ,  C07D401/04 ,  C07D405/04 ,  C07D487/04 ,  C07D403/04

CPC分类号： C07D471/04 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D487/04

摘要： The present invention is directed to compounds of formula I and 1a: which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

摘要翻译： 本发明涉及式I和1a的化合物：其是原肌球蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此可用于治疗疼痛，炎症，癌症，再狭窄，动脉粥样硬化，牛皮癣，血栓形成， 与神经生长因子（NGF）受体TrkA的异常活动相关的疾病，失调，损伤或功能障碍，或与脱髓鞘或脱髓鞘相关的疾病或病症。

公开(公告)号：US09102673B2

公开(公告)日：2015-08-11

申请号：US14131861

申请日：2012-07-06

申请人： Barbara Hanney ,  Peter Manley ,  Michael T. Rudd ,  John M. Sanders ,  Shawn J. Stachel ,  Darrell Henze

发明人： Barbara Hanney ,  Peter Manley ,  Michael T. Rudd ,  John M. Sanders ,  Shawn J. Stachel ,  Darrell Henze

IPC分类号： A61K31/437 ,  C07D471/04 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D487/04

CPC分类号： C07D471/04 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D487/04

摘要： The present invention is directed to compounds of formula I and Ia: which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

摘要翻译： 本发明涉及式I和Ia的化合物：它们是原肌球蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此可用于治疗疼痛，炎症，癌症，再狭窄，动脉粥样硬化，牛皮癣，血栓形成， 与神经生长因子（NGF）受体TrkA的异常活动相关的疾病，失调，损伤或功能障碍，或与脱髓鞘或脱髓鞘相关的疾病或病症。